VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q88722929  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241221010857.0
008     241221nneanz||abbn n and d
035 ‎‡a  (WKP)Q88722929‏
024 ‎‡a  0000-0003-3104-3460‏ ‎‡2  orcid‏
024 ‎‡a  56951376300‏ ‎‡2  scopus‏
035 ‎‡a  (OCoLC)Q88722929‏
100 0 ‎‡a  María Asunción Esteve-Pastor‏ ‎‡c  researcher‏ ‎‡9  en‏
400 0 ‎‡a  María Asunción Esteve-Pastor‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's A Nurse-led Atrial Fibrillation Clinic: Impact on Anticoagulation Therapy and Clinical Outcomes‏
670 ‎‡a  Author's A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World" vs Clinical Trials‏
670 ‎‡a  Author's Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality‏
670 ‎‡a  Author's Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial‏
670 ‎‡a  Author's Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIIA Registry‏
670 ‎‡a  Author's Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients‏
670 ‎‡a  Author's Chronic Kidney Disease and Third-Generation P2Y12 Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year‏
670 ‎‡a  Author's Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients‏
670 ‎‡a  Author's Conservatively managed patients with non-ST-segment elevation acute coronary syndrome are undertreated with indicated medicines‏
670 ‎‡a  Author's Differences of Matrix Metalloproteinase 2 Expression between Left and Right Ventricles in Response to Nandrolone Decanoate and/or Swimming Training in Mice‏
670 ‎‡a  Author's Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study‏
670 ‎‡a  Author's Disparities in the Estimation of Glomerular Filtration Rate According to Cockcroft-Gault, Modification of Diet in Renal Disease-4, and Chronic Kidney Disease Epidemiology Collaboration Equations and Relation With Outcomes in Patients With Acute Coro‏
670 ‎‡a  Author's Do physicians correctly calculate thromboembolic risk scores? A comparison of concordance between manual and computer-based calculation of CHADS2 and CHA2 DS2 -VASc scores‏
670 ‎‡a  Author's Enhancing the 'real world' prediction of cardiovascular events and major bleeding with the CHA2DS2-VASc and HAS-BLED scores using multiple biomarkers.‏
670 ‎‡a  Author's Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in 'real-world' atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients‏
670 ‎‡a  Author's Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation‏
670 ‎‡a  Author's Evaluation of HAS-BLED and ORBIT Bleeding Risk Scores in Nonvalvular Atrial Fibrillation Patients Receiving Oral Anticoagulants‏
670 ‎‡a  Author's Heart Failure and Cardiac Events: Is a Consecutive Measurement of Biomarkers a Simple and Practical Approach?‏
670 ‎‡a  Author's Hypertension and Atrial Fibrillation: Balancing Stroke and Bleeding Risks‏
670 ‎‡a  Author's Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome‏
670 ‎‡a  Author's Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation‏
670 ‎‡a  Author's Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?‏
670 ‎‡a  Author's Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project.‏
670 ‎‡a  Author's Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA2DS2-VASc Scores‏
670 ‎‡a  Author's Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry.‏
670 ‎‡a  Author's Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation‏
670 ‎‡a  Author's New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?‏
670 ‎‡a  Author's Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation‏
670 ‎‡a  Author's One-year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry‏
670 ‎‡a  Author's Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A report from the FANTASIIA registry‏
670 ‎‡a  Author's Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation.‏
670 ‎‡a  Author's Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF Bleeding Scores‏
670 ‎‡a  Author's Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA2DS2-VASc and HAS-BLED.‏
670 ‎‡a  Author's Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry.‏
670 ‎‡a  Author's Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol.‏
670 ‎‡a  Author's Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores‏
670 ‎‡a  Author's Relation of quality of anticoagulation control with different management systems amongst patients with atrial fibrillation: Data from FANTASIIA Registry‏
670 ‎‡a  Author's Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIIA Registry.‏
670 ‎‡a  Author's Relationship of adverse events to quality of anticoagulation control in atrial fibrillation patients with diabetes: Real-world data from the FANTASIIA registry‏
670 ‎‡a  Author's Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project.‏
670 ‎‡a  Author's Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores‏
670 ‎‡a  Author's Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes.‏
670 ‎‡a  Author's The SAMe-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation.‏
670 ‎‡a  Author's The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal‏
670 ‎‡a  Author's Therapeutic management and one-year outcomes in elderly patients with acute coronary syndrome‏
670 ‎‡a  Author's Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy‏
670 ‎‡a  Author's Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation.‏
909 ‎‡a  (orcid) 0000000331043460‏ ‎‡9  1‏
909 ‎‡a  (scopus) 56951376300‏ ‎‡9  1‏
919 ‎‡a  longtermstrokeriskpredictioninpatientswithatrialfibrillationcomparisonoftheabcstrokeandcha2ds2vascscores‏ ‎‡A  Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA2DS2-VASc Scores‏ ‎‡9  1‏
919 ‎‡a  lowbodyweightandclinicaloutcomesinacutecoronarysyndromepatientsresultsoftheachillesregistry‏ ‎‡A  Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry.‏ ‎‡9  1‏
919 ‎‡a  murciaatrialfibrillationproject2protocolforaprospectiveobservationalstudyinpatientswithatrialfibrillation‏ ‎‡A  Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation‏ ‎‡9  1‏
919 ‎‡a  usefulnessofthe2macescoretopredictsadversecardiovasculareventsinpatientswithatrialfibrillation‏ ‎‡A  Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation.‏ ‎‡9  1‏
919 ‎‡a  treatmentstrategiesforpatientswithatrialfibrillationandanticoagulantassociatedintracranialhemorrhageanoverviewofthepharmacotherapy‏ ‎‡A  Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy‏ ‎‡9  1‏
919 ‎‡a  therapeuticmanagementand1yearoutcomesinelderlypatientswithacutecoronarysyndrome‏ ‎‡A  Therapeutic management and one-year outcomes in elderly patients with acute coronary syndrome‏ ‎‡9  1‏
919 ‎‡a  useofbiomarkersinclinicalmanagementguidelinesacriticalappraisal‏ ‎‡A  The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal‏ ‎‡9  1‏
919 ‎‡a  samett2r2scoreanddecisionmakingbetweenavitaminkantagonistoranonvitaminkantagonistoralanticoagulantinpatientswithatrialfibrillation‏ ‎‡A  The SAMe-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation.‏ ‎‡9  1‏
919 ‎‡a  temporaltrendsintheuseofantiplatelettherapyinpatientswithacutecoronarysyndromes‏ ‎‡A  Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes.‏ ‎‡9  1‏
919 ‎‡a  strokeandthromboembolisminwarfarintreatedpatientswithatrialfibrillationcomparingthecha2ds2vascandgarfieldafriskscores‏ ‎‡A  Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores‏ ‎‡9  1‏
919 ‎‡a  solublefibrinmonomercomplexandpredictionofcardiovasculareventsinatrialfibrillationtheobservationalmurciaatrialfibrillationproject‏ ‎‡A  Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project.‏ ‎‡9  1‏
919 ‎‡a  relationshipofadverseeventstoqualityofanticoagulationcontrolinatrialfibrillationpatientswithdiabetesrealworlddatafromthefantasiiaregistry‏ ‎‡A  Relationship of adverse events to quality of anticoagulation control in atrial fibrillation patients with diabetes: Real-world data from the FANTASIIA registry‏ ‎‡9  1‏
919 ‎‡a  relationofrenaldysfunctiontoqualityofanticoagulationcontrolinpatientswithatrialfibrillationthefantasiiaregistry‏ ‎‡A  Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIIA Registry.‏ ‎‡9  1‏
919 ‎‡a  relationofqualityofanticoagulationcontrolwithdifferentmanagementsystemsamongstpatientswithatrialfibrillationdatafromfantasiiaregistry‏ ‎‡A  Relation of quality of anticoagulation control with different management systems amongst patients with atrial fibrillation: Data from FANTASIIA Registry‏ ‎‡9  1‏
919 ‎‡a  refiningstrokeandbleedingpredictioninatrialfibrillationbyaddingconsecutivebiomarkerstoclinicalriskscores‏ ‎‡A  Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores‏ ‎‡9  1‏
919 ‎‡a  reducedtimeintherapeuticrangeandhighermortalityinatrialfibrillationpatientstakingacenocoumarol‏ ‎‡A  Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol.‏ ‎‡9  1‏
919 ‎‡a  qualityoforalanticoagulationwithvitaminkantagonistsinrealworldpatientswithatrialfibrillationareportfromtheprospectivemulticentrefantasiiaregistry‏ ‎‡A  Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry.‏ ‎‡9  1‏
919 ‎‡a  predictionoflongtermnetclinicaloutcomesusingthetimiafscorecomparisonwithcha2ds2vascandhasbled‏ ‎‡A  Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA2DS2-VASc and HAS-BLED.‏ ‎‡9  1‏
919 ‎‡a  predictingbleedingeventsinanticoagulatedpatientswithatrialfibrillationacomparisonbetweenthehasbledandgarfieldafbleedingscores‏ ‎‡A  Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF Bleeding Scores‏ ‎‡9  1‏
919 ‎‡a  pharmacogeneticsofvitaminkantagonistsandbleedingriskpredictioninatrialfibrillation‏ ‎‡A  Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation.‏ ‎‡9  1‏
919 ‎‡a  peripheralarterydiseaseandclinicaloutcomesinpatientswithatrialfibrillationareportfromthefantasiiaregistry‏ ‎‡A  Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A report from the FANTASIIA registry‏ ‎‡9  1‏
919 ‎‡a  nurseledatrialfibrillationclinicimpactonanticoagulationtherapyandclinicaloutcomes‏ ‎‡A  A Nurse-led Atrial Fibrillation Clinic: Impact on Anticoagulation Therapy and Clinical Outcomes‏ ‎‡9  1‏
919 ‎‡a  propensityscorematchedcomparisonofclinicaloutcomesinatrialfibrillationpatientstakingvitaminkantagonistscomparingtherealworldvsclinicaltrials‏ ‎‡A  A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World" vs Clinical Trials‏ ‎‡9  1‏
919 ‎‡a  1yearefficacyandsafetyofprasugrelandticagrelorinpatientswithacutecoronarysyndromesresultsfromaprospectiveandmulticentreachillesregistry‏ ‎‡A  One-year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry‏ ‎‡9  1‏
919 ‎‡a  antiplatelettherapycombinedwithacenocoumarolinrelationtomajorbleedingischaemicstrokeandmortality‏ ‎‡A  Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality‏ ‎‡9  1‏
919 ‎‡a  assessingbleedingriskinatrialfibrillationpatientscomparingableedingriskscorebasedonlyonmodifiablebleedingriskfactorsagainstthehasbledscoretheamadeustrial‏ ‎‡A  Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial‏ ‎‡9  1‏
919 ‎‡a  associationofbodymassindexwithclinicaloutcomesinpatientswithatrialfibrillationareportfromthefantasiiaregistry‏ ‎‡A  Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIIA Registry‏ ‎‡9  1‏
919 ‎‡a  cessationoforalanticoagulationisanimportantriskfactorforstrokeandmortalityinatrialfibrillationpatients‏ ‎‡A  Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients‏ ‎‡9  1‏
919 ‎‡a  nonvitaminkantagonistoralanticoagulantsimpactofnonadherenceanddiscontinuation‏ ‎‡A  Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation‏ ‎‡9  1‏
919 ‎‡a  newapproachestotheroleofthrombininacutecoronarysyndromesquovadisbivalirudinadirectthrombininhibitor‏ ‎‡A  New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?‏ ‎‡9  1‏
919 ‎‡a  chronickidneydiseaseand3generationp2y12inhibitorsuseinpatientswithacutecoronarysyndromeimpactontheprognosisat1year‏ ‎‡A  Chronic Kidney Disease and Third-Generation P2Y12 Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year‏ ‎‡9  1‏
919 ‎‡a  comparisonofthe2maceandtimiafscoresforcompositeclinicaloutcomesinanticoagulatedatrialfibrillationpatients‏ ‎‡A  Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients‏ ‎‡9  1‏
919 ‎‡a  conservativelymanagedpatientswithnonstsegmentelevationacutecoronarysyndromeareundertreatedwithindicatedmedicines‏ ‎‡A  Conservatively managed patients with non-ST-segment elevation acute coronary syndrome are undertreated with indicated medicines‏ ‎‡9  1‏
919 ‎‡a  differencesofmatrixmetalloproteinase2expressionbetweenleftandrightventriclesinresponsetonandrolonedecanoateandorswimmingtraininginmice‏ ‎‡A  Differences of Matrix Metalloproteinase 2 Expression between Left and Right Ventricles in Response to Nandrolone Decanoate and/or Swimming Training in Mice‏ ‎‡9  1‏
919 ‎‡a  directanticoagulantsversusvitaminkantagonistsinpatientsaged80yearsorolderwithatrialfibrillationinarealworldnationwideregistryinsightsfromthefantasiiastudy‏ ‎‡A  Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study‏ ‎‡9  1‏
919 ‎‡a  disparitiesintheestimationofglomerularfiltrationrateaccordingtocockcroftgaultmodificationofdietinrenaldisease4andchronickidneydiseaseepidemiologycollaborationequationsandrelationwithoutcomesinpatientswithacutecoro‏ ‎‡A  Disparities in the Estimation of Glomerular Filtration Rate According to Cockcroft-Gault, Modification of Diet in Renal Disease-4, and Chronic Kidney Disease Epidemiology Collaboration Equations and Relation With Outcomes in Patients With Acute Coro‏ ‎‡9  1‏
919 ‎‡a  dophysicianscorrectlycalculatethromboembolicriskscoresacomparisonofconcordancebetweenmanualandcomputerbasedcalculationofchads2andcha2ds2vascscores‏ ‎‡A  Do physicians correctly calculate thromboembolic risk scores? A comparison of concordance between manual and computer-based calculation of CHADS2 and CHA2 DS2 -VASc scores‏ ‎‡9  1‏
919 ‎‡a  enhancingtherealworldpredictionofcardiovasculareventsandmajorbleedingwiththecha2ds2vascandhasbledscoresusingmultiplebiomarkers‏ ‎‡A  Enhancing the 'real world' prediction of cardiovascular events and major bleeding with the CHA2DS2-VASc and HAS-BLED scores using multiple biomarkers.‏ ‎‡9  1‏
919 ‎‡a  estimatedabsoluteeffectsonefficacyandsafetyoutcomesofusingnonvitaminkantagonistoralanticoagulantsinrealworldatrialfibrillationpatientsacomparisonwithoptimallyacenocoumarolanticoagulatedpatients‏ ‎‡A  Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in 'real-world' atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients‏ ‎‡9  1‏
919 ‎‡a  estimatedeffectivenessandsafetyofnonvitaminkantagonistoralanticoagulantscomparedwithoptimallyacenocoumarolanticoagulatedrealworldinpatientswithatrialfibrillation‏ ‎‡A  Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation‏ ‎‡9  1‏
919 ‎‡a  evaluationofhasbledandorbitbleedingriskscoresinnonvalvularatrialfibrillationpatientsreceivingoralanticoagulants‏ ‎‡A  Evaluation of HAS-BLED and ORBIT Bleeding Risk Scores in Nonvalvular Atrial Fibrillation Patients Receiving Oral Anticoagulants‏ ‎‡9  1‏
919 ‎‡a  heartfailureandcardiaceventsisaconsecutivemeasurementofbiomarkersasimpleandpracticalapproach‏ ‎‡A  Heart Failure and Cardiac Events: Is a Consecutive Measurement of Biomarkers a Simple and Practical Approach?‏ ‎‡9  1‏
919 ‎‡a  hypertensionandatrialfibrillationbalancingstrokeandbleedingrisks‏ ‎‡A  Hypertension and Atrial Fibrillation: Balancing Stroke and Bleeding Risks‏ ‎‡9  1‏
919 ‎‡a  impactofanemiaasriskfactorformajorbleedingandmortalityinpatientswithacutecoronarysyndrome‏ ‎‡A  Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome‏ ‎‡9  1‏
919 ‎‡a  importanceoftimeintherapeuticrangeonbleedingriskpredictionusingclinicalriskscoresinpatientswithatrialfibrillation‏ ‎‡A  Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation‏ ‎‡9  1‏
919 ‎‡a  istheorbitbleedingriskscoresuperiortothehasbledscoreinanticoagulatedatrialfibrillationpatients‏ ‎‡A  Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?‏ ‎‡9  1‏
919 ‎‡a  longtermbleedingriskpredictioninrealworldpatientswithatrialfibrillationcomparisonofthehasbledandabcbleedingriskscoresthemurciaatrialfibrillationproject‏ ‎‡A  Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project.‏ ‎‡9  1‏
996 ‎‡2  LC|n 2009015422‏
996 ‎‡2  SUDOC|099031396‏
996 ‎‡2  ISNI|0000000499613885‏
996 ‎‡2  DNB|1194847854‏
996 ‎‡2  LC|no2018123981‏
996 ‎‡2  SUDOC|095245731‏
996 ‎‡2  J9U|987007455468505171‏
996 ‎‡2  NII|DA06136537‏
996 ‎‡2  BNE|XX1471718‏
996 ‎‡2  BNE|XX1719468‏
996 ‎‡2  SUDOC|142752924‏
996 ‎‡2  ISNI|000000004217240X‏
996 ‎‡2  BNE|XX4756534‏
996 ‎‡2  BNE|XX6274116‏
996 ‎‡2  LC|no 96062193‏
996 ‎‡2  BNE|XX5757376‏
996 ‎‡2  SUDOC|22698799X‏
996 ‎‡2  PTBNP|206909‏
996 ‎‡2  RERO|A000072369‏
996 ‎‡2  ISNI|0000000080074544‏
996 ‎‡2  LC|no2013000923‏
996 ‎‡2  LC|n 2009026251‏
996 ‎‡2  JPG|500094159‏
996 ‎‡2  PTBNP|1608310‏
996 ‎‡2  DNB|1335021612‏
996 ‎‡2  BNE|XX4580479‏
996 ‎‡2  LC|n 86120450‏
996 ‎‡2  BNE|XX1095016‏
996 ‎‡2  SUDOC|059903759‏
996 ‎‡2  LC|no2018001263‏
996 ‎‡2  ISNI|0000000113750351‏
996 ‎‡2  BNE|XX1461879‏
996 ‎‡2  BNF|17792258‏
996 ‎‡2  BLBNB|001581398‏
996 ‎‡2  NUKAT|n 2017221786‏
996 ‎‡2  ISNI|0000000060544561‏
996 ‎‡2  SUDOC|131388029‏
996 ‎‡2  BNC|981058610223606706‏
996 ‎‡2  LC|n 2018002224‏
996 ‎‡2  ISNI|0000000045557559‏
996 ‎‡2  BNE|XX1224052‏
996 ‎‡2  BNE|XX1689898‏
996 ‎‡2  RERO|A024703981‏
996 ‎‡2  LC|no2002063140‏
996 ‎‡2  BNE|XX905635‏
996 ‎‡2  BNC|981058521572406706‏
996 ‎‡2  SUDOC|254198910‏
996 ‎‡2  BNF|13479159‏
996 ‎‡2  SUDOC|281645221‏
996 ‎‡2  ISNI|0000000023737487‏
996 ‎‡2  ISNI|0000000459877026‏
996 ‎‡2  BNE|XX1602965‏
996 ‎‡2  SUDOC|156493691‏
996 ‎‡2  BNE|XX1540421‏
996 ‎‡2  LC|n 2006061159‏
996 ‎‡2  BNE|XX1247526‏
996 ‎‡2  BNE|XX941485‏
996 ‎‡2  CAOONL|ncf11283813‏
996 ‎‡2  BNC|981058511489906706‏
996 ‎‡2  DNB|106069154X‏
996 ‎‡2  BNC|981058508648306706‏
996 ‎‡2  LC|n 78025424‏
996 ‎‡2  SUDOC|110543823‏
996 ‎‡2  BNE|XX1516648‏
996 ‎‡2  DNB|1215928785‏
996 ‎‡2  ISNI|0000000038983517‏
996 ‎‡2  BNC|981058512017006706‏
996 ‎‡2  BNF|16076358‏
996 ‎‡2  ISNI|0000000059333206‏
996 ‎‡2  LC|n 90692191‏
996 ‎‡2  BIBSYS|10043545‏
996 ‎‡2  NSK|000181826‏
996 ‎‡2  ISNI|0000000059366593‏
996 ‎‡2  DNB|1178442853‏
996 ‎‡2  ISNI|0000000355813837‏
996 ‎‡2  J9U|987012501035505171‏
996 ‎‡2  ISNI|0000000069611580‏
996 ‎‡2  BNC|981058515278206706‏
996 ‎‡2  ISNI|0000000030679481‏
996 ‎‡2  BNF|12178033‏
996 ‎‡2  SUDOC|119727242‏
996 ‎‡2  SUDOC|20418410X‏
996 ‎‡2  ISNI|0000000115566187‏
996 ‎‡2  LC|n 2020007643‏
996 ‎‡2  ISNI|0000000498225194‏
996 ‎‡2  ISNI|0000000080152610‏
996 ‎‡2  CAOONL|ncf10322726‏
996 ‎‡2  DNB|1057104035‏
996 ‎‡2  BNE|XX1063681‏
996 ‎‡2  J9U|987007411254405171‏
996 ‎‡2  CAOONL|ncf10666101‏
996 ‎‡2  ISNI|000000005933548X‏
996 ‎‡2  LC|nb2010011358‏
996 ‎‡2  ISNI|0000000059481209‏
996 ‎‡2  BNC|981058519609106706‏
996 ‎‡2  ISNI|0000000059240747‏
996 ‎‡2  SUDOC|255448511‏
996 ‎‡2  BNE|XX4794551‏
996 ‎‡2  LC|no 99013115‏
996 ‎‡2  BIBSYS|9013865‏
996 ‎‡2  ISNI|0000000037254777‏
996 ‎‡2  ISNI|0000000496601184‏
996 ‎‡2  DNB|1148559485‏
996 ‎‡2  BNE|XX1071233‏
996 ‎‡2  DNB|171579658‏
996 ‎‡2  BNF|15053766‏
996 ‎‡2  BNE|XX1390909‏
996 ‎‡2  DNB|1056713755‏
996 ‎‡2  SUDOC|050234587‏
996 ‎‡2  BNF|12396894‏
996 ‎‡2  BNC|981058508635406706‏
996 ‎‡2  BNE|XX5460361‏
996 ‎‡2  LC|n 2022040605‏
996 ‎‡2  BNCHL|10000000000000000096214‏
996 ‎‡2  DNB|129879800‏
996 ‎‡2  SUDOC|200288865‏
996 ‎‡2  BNE|XX6469828‏
996 ‎‡2  SUDOC|147907756‏
996 ‎‡2  BNE|XX1166417‏
996 ‎‡2  BNE|XX5527129‏
996 ‎‡2  SUDOC|147386136‏
996 ‎‡2  SUDOC|237688603‏
996 ‎‡2  ISNI|0000000065007415‏
996 ‎‡2  DNB|1157214312‏
996 ‎‡2  LC|no 99034997‏
996 ‎‡2  ISNI|0000000060985164‏
996 ‎‡2  DNB|115665694X‏
996 ‎‡2  ISNI|0000000118256360‏
996 ‎‡2  RERO|A003674078‏
996 ‎‡2  LC|n 96120386‏
996 ‎‡2  BNE|XX887256‏
996 ‎‡2  RERO|A024582243‏
996 ‎‡2  BNE|XX4708147‏
996 ‎‡2  ISNI|0000000079701555‏
996 ‎‡2  BNE|XX1143047‏
996 ‎‡2  BNE|XX997291‏
996 ‎‡2  BNC|981061050175806706‏
996 ‎‡2  LC|n 81122249‏
996 ‎‡2  LC|n 2018018025‏
996 ‎‡2  BNF|15899600‏
996 ‎‡2  DNB|1056461551‏
996 ‎‡2  NKC|mub20211132133‏
996 ‎‡2  BNE|XX1327266‏
996 ‎‡2  BNE|XX4849663‏
996 ‎‡2  ISNI|0000000072691710‏
996 ‎‡2  LC|no2017059806‏
996 ‎‡2  SUDOC|157224651‏
996 ‎‡2  BNE|XX1019479‏
996 ‎‡2  LC|n 2001107688‏
996 ‎‡2  BNC|981058513296506706‏
996 ‎‡2  BNE|XX1134149‏
996 ‎‡2  DNB|1150724315‏
996 ‎‡2  ISNI|0000000063162489‏
996 ‎‡2  BNE|XX878013‏
996 ‎‡2  SUDOC|070261806‏
996 ‎‡2  LC|n 85325409‏
996 ‎‡2  LC|n 88114789‏
996 ‎‡2  ISNI|0000000059238030‏
996 ‎‡2  BNF|15517842‏
996 ‎‡2  SUDOC|154008605‏
996 ‎‡2  RERO|A003674102‏
996 ‎‡2  ISNI|000000011887947X‏
996 ‎‡2  BNE|XX835407‏
996 ‎‡2  NUKAT|n 2013168427‏
996 ‎‡2  BNE|XX1458218‏
996 ‎‡2  SUDOC|228848482‏
996 ‎‡2  BNE|XX1150754‏
996 ‎‡2  SUDOC|157115542‏
996 ‎‡2  SUDOC|05976533X‏
996 ‎‡2  SUDOC|033064644‏
996 ‎‡2  LC|n 96038016‏
996 ‎‡2  BNE|XX841234‏
996 ‎‡2  BIBSYS|97012802‏
996 ‎‡2  DNB|1264256175‏
996 ‎‡2  BNE|XX1378670‏
996 ‎‡2  BNC|981058524984706706‏
996 ‎‡2  NYNYRILM|335275‏
996 ‎‡2  BNCHL|10000000000000000083863‏
996 ‎‡2  ISNI|0000000024695960‏
996 ‎‡2  ISNI|0000000037670092‏
996 ‎‡2  ISNI|0000000118611801‏
996 ‎‡2  DNB|171733312‏
996 ‎‡2  SUDOC|231683839‏
996 ‎‡2  BNE|XX1153393‏
996 ‎‡2  DNB|1157320368‏
996 ‎‡2  LC|no2014058637‏
996 ‎‡2  BNE|XX820782‏
996 ‎‡2  DNB|1325652954‏
996 ‎‡2  BNF|14507047‏
996 ‎‡2  BNE|XX6092318‏
996 ‎‡2  DNB|120097427‏
996 ‎‡2  LC|no2024014548‏
996 ‎‡2  BNE|XX1585700‏
996 ‎‡2  LC|n 2009026252‏
996 ‎‡2  BNE|XX1107130‏
996 ‎‡2  BNF|13491762‏
996 ‎‡2  BNE|XX5195714‏
996 ‎‡2  NSK|000284319‏
996 ‎‡2  ISNI|0000000079710531‏
996 ‎‡2  ISNI|0000000032379837‏
996 ‎‡2  BNE|XX1062105‏
996 ‎‡2  BNE|XX5430738‏
996 ‎‡2  SUDOC|084591528‏
996 ‎‡2  NTA|151472165‏
996 ‎‡2  DNB|1155309278‏
996 ‎‡2  DNB|143771531‏
996 ‎‡2  BNC|981058513603606706‏
996 ‎‡2  BNE|XX4578535‏
996 ‎‡2  BNE|XX1157001‏
996 ‎‡2  ISNI|0000000059705313‏
996 ‎‡2  BNE|XX1719003‏
996 ‎‡2  LC|no 99033365‏
996 ‎‡2  BNE|XX1083921‏
996 ‎‡2  BNC|981061035120306706‏
996 ‎‡2  LC|n 2024023365‏
996 ‎‡2  ISNI|0000000073311089‏
996 ‎‡2  SUDOC|030346231‏
996 ‎‡2  SUDOC|181743132‏
996 ‎‡2  ISNI|0000000059246479‏
996 ‎‡2  ISNI|0000000382890184‏
996 ‎‡2  LC|no 99015887‏
996 ‎‡2  BNC|981058524372806706‏
996 ‎‡2  ISNI|0000000109383245‏
996 ‎‡2  BNF|13491839‏
996 ‎‡2  DNB|1146416822‏
996 ‎‡2  NII|DA19567203‏
996 ‎‡2  LC|n 85122111‏
996 ‎‡2  LC|n 81006786‏
996 ‎‡2  BNE|XX5608146‏
996 ‎‡2  BNE|XX1048812‏
996 ‎‡2  BNC|981058523661206706‏
996 ‎‡2  SUDOC|274978466‏
996 ‎‡2  PLWABN|9810808892205606‏
996 ‎‡2  LC|no 00072886‏
996 ‎‡2  BNE|XX4749905‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏